SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (3504)4/21/2001 12:23:53 AM
From: aknahow  Read Replies (3) | Respond to of 52153
 
From TSC.

thestreet.com

Short the biotechs.<g> But Kris Jenner from T. Rowe Price was more positive about biotechs on Wall Street Week than one would ever have imagined he could be. But ever time he began to mention the area he was asked a question about something else. He did seem to favor the smaller ones, but never defined small. said essentially there were 12 to 16 that were in "sweet spot" area, right now.

Jenner was at one time a M.D and also a football player. So that means he is just as qualified as the TSC writer. Perhaps more so, since she never played football.



To: Biomaven who wrote (3504)4/21/2001 11:46:34 AM
From: scaram(o)uche  Respond to of 52153
 
Shorting in biotech is, IMO, a fool's game.

One is locked into a given issue waiting for a payoff that is lower than 100%.

If you're successful, as Avalon has been for a given period, it's still playing for chump change.